Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Lexaria Bioscience Corp (LXX.CN)

Lexaria Bioscience Corp (LXX.CN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Lexaria Bioscience Corp 740 McCurdy Road Suite 100 Kelowna BC V1X 2P7 CAN

P: 250-765-6424

Description:

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH has the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio.

Key Statistics

Overview:

Market Capitalization, $K 42,270
Shares Outstanding, K 5,104
Annual Sales, $ 723 K
Annual Net Income, $ -4,027 K
Last Quarter Sales, $ 100 K
Last Quarter Net Income, $ -2,383 K
60-Month Beta 1.81
% of Institutional Shareholders 1.39%

Growth:

1-Year Return -21.13%
3-Year Return -88.48%
5-Year Return 75.00%
5-Year Revenue Growth 77.76%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.86
EPS Growth vs. Prev Year 0.00%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-30 on 01/12/21

LXX.CN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -71.49%
Return-on-Assets % -70.91%
Profit Margin % -557.19
Net Margin % -39.82
Debt/Equity 0.00
Price/Sales 28.56
Price/Book 2.99
Book Value/Share 2.85
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar